Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection

• DOI: 10.1128/aac.06355-11
• Publication Date: 2012-05-30T03:24:37Z
• Authors: Anna Trzasko; Jennifer A. Leeds; Jens Praestgaard; Matthew J. LaMarche; David McKenney
• Keywords: Mesocricetus

LFF571 is a novel semisynthetic thiopeptide antibiotic with potent activity against variety of Gram-positive pathogens, including Clostridium difficile. In vivo efficacy was compared to vancomycin in hamster model C. difficile infection (CDI). Infection induced Golden Syrian hamsters using toxigenic strain Treatment started 24 h postinfection and consisted saline, vancomycin, or LFF571. Cox regression used analyze survival data from cohort animals evaluated across seven serial experimental groups treated at 20 mg/kg, 5 vehicle alone. Survival right censored; were not observed beyond day 21. At death end study, cecal contents tested for toxins A B. summary, the showed that mg/kg decreased risk by 79% (P < 0.0001) 69% = 0.0022) saline respectively. Further analysis pooled indicated benefit treatment due primarily decrease recurrence after treatment. Animals successfully had no detectable toxin. Overall, more efficacious lower dose, fewer recurrences, than CDI. being assessed humans safety infections.